Background: Highly efficient capture and detection of circulating tumor cells (CTCs) remain elusive mainly because of their extremely low concentration in patients’ peripheral blood. Methods: We present an approach for the simultaneous capturing, isolation, and detection of CTCs using an immuno-fluorescent magnetic nanobead system (iFMNS) coated with a monoclonal anti-EpCAM antibody. Results: The developed antibody nanobead system allows magnetic isolation and fluorescent-based quantification of CTCs. The expression of EpCAM on the surface of captured CTCs could be directly visualized without additional immune-fluorescent labeling. Our approach is shown to result in a 70–95% capture efficiency of CTCs, and 95% of the captured cells remain viable. Using our approach, the isolated cells could be directly used for culture, reverse transcription-polymerase chain reaction (RT-PCR), and immunocytochemistry (ICC) identification. We applied iFMNS for testing CTCs in peripheral blood samples from a lung cancer patient. Conclusions: It is suggested that our iFMNS approach would be a promising tool for CTCs enrichment and detection in one step. Graphic
Highly efficient capture and detection of circulating tumor cells (CTCs) remain elusive mainly because of their extremely low concentration in the peripheral blood of patients. Herein, we present an approach for the simultaneous capturing, isolation, and detection of CTCs using an immuno-fluorescent magnetic nanobead system (iFMNS) coated with a monoclonal anti-EpCAM antibody. The developed antibody nanobead system allows magnetic isolation and fluorescent-based quantification of CTCs. The expression of EpCAM on the surface of captured CTCs could be directly visualized without additional immune-fluorescent labeling. Our approach is shown to result in a 70 - 95% capture efficiency of CTCs, and 95% of the captured cells remain viable. Using our approach, the isolated cells could be directly used for culture, reverse transcription-polymerase chain reaction (RT-PCR), and immunocytochemistry (ICC) identification. We applied iFMNS for testing CTCs in peripheral blood samples from a lung cancer patient, which suggested that this approach would be a promising tool for CTCs enrichment and detection in one step.
Developing a quantum dot (QD) nanobeads-based lateral-flow assay (LFA) is of great importance for achieving ultrasen-sitive, quantitative, and rapid testing of clinical specimens at the point-of-care. However, the QD nanobeads currently used in LFA still have drawbacks such as large particle size, which leads to high background, easy aggregation, and poor fluidity. To address these issues, a promising strategy is to utilize plasmonic energy transfer from gold nanoparticles (AuNPs) to QDs in order to create smaller size and brighter fluorescent QD nanobeads, without simply increasing the amount of QDs encapsulated in the nanobeads. In this study, we prepared the plasmon-enhanced quantum dot nano-beads (PEQNB) by encapsulating AuNPs and QDs into polymer nanobeads using the versatile emulsion-solvent evapora-tion method. We were able to detect as low as ~4347 PEQNBs nanoparticles using a gel imager, which is 14.6 times brighter than the QD nanobeads of a similar size. Compared to QD nanobeads of similar size, the PEQNB-based LFA for interleukin-6 detection exhibited higher fluorescent signal and lower background. The detection limit of PEQNB-based LFA was 1.63-fold higher than that of QD nanobeads. Furthermore, compared to larger-sized QD nanobeads with aver-age diameter of 131.1nm, PEQNB with average diameter of 78.6 nm based LFA exhibited similar levels of fluorescence intensity, but 1.55-fold lower background signal and 1.44-fold lower detection limits. This work demonstrates that opti-mized plasmon-enhanced QD nanobeads can further increase the sensitivity and lower the background signals of ultra-sensitive QD nanobeads-based LFA for disease diagnosis at point-of-care.